Edition:
India

BioInvent International AB (BINV.ST)

BINV.ST on Stockholm Stock Exchange

1.54SEK
8:08pm IST
Change (% chg)

-0.02kr (-1.03%)
Prev Close
1.56kr
Open
1.54kr
Day's High
1.56kr
Day's Low
1.53kr
Volume
781,891
Avg. Vol
2,337,870
52-wk High
1.96kr
52-wk Low
0.82kr

Latest Key Developments (Source: Significant Developments)

BioInvent Q3 Loss After Tax Narrows To SEK 32.9 Million
Thursday, 29 Oct 2020 

Oct 29 (Reuters) - BioInvent International AB ::BIOINVENT INTERIM REPORT JANUARY 1 - SEPTEMBER 30, 2020.Q3 NET SALES SEK 16.3 (18.1) MILLION..Q3 LOSS AFTER TAX SEK 32.9 MILLION VERSUS LOSS SEK 37.1 MILLION YEAR AGO.BIOINVENT - BIOINVENT IS WELL POSITIONED TO CONTINUE TO DELIVER ON PROMISE OF OUR PIPELINE..  Full Article

BioInvent Q2 Loss After Tax Widens To SEK 39.3 Mln
Thursday, 27 Aug 2020 

Aug 27 (Reuters) - BioInvent International AB ::BIOINVENT INTERIM REPORT JANUARY 1 - JUNE 30, 2020.Q2 NET SALES SEK 15.6 (32.9) MILLION.Q2 LOSS AFTER TAX SEK -39.3 (-32.8) MILLION.  Full Article

Bioinvent to launch SEK 139 mln repair rights issue
Thursday, 9 Jul 2020 

July 9 (Reuters) - BioInvent International AB ::BIOINVENT'S BOARD OF DIRECTORS RESOLVE ON A REPAIR RIGHTS ISSUE OF A MAXIMUM OF APPROX. SEK 139 MILLION, FOLLOWING THE SUCCESSFULLY COMPLETED DIRECTED SHARE ISSUE OF APPROX. SEK 487 MILLION.BIOINVENT SAYS SUBSCRIPTION PRICE IN RIGHTS ISSUE WILL BE SEK 1.38 PER SHARE, WHICH IS SAME AS PRICE PER SHARE PAID IN DIRECTED SHARE ISSUE.BIOINVENT SAYS PROVIDED THAT RIGHTS ISSUE IS FULLY SUBSCRIBED A MAXIMUM NUMBER OF 100,527,062 SHARES WILL BE ISSUED AND COMPANY WILL RECEIVE APPROXIMATELY SEK 139 MILLION BEFORE TRANSACTION COSTS..BIOINVENT SAYS NET PROCEEDS FROM RIGHTS ISSUE ARE MAINLY INTENDED FOR PROGRESSING AND EXPANDING CLINICAL DEVELOPMENT OF BI-1206,.  Full Article

Finansinspektionen Says Van Herk Investments B.V. Increases Stake In Bioinvent
Wednesday, 8 Jul 2020 

July 8 (Reuters) - BioInvent International AB ::FINANSINSPEKTIONEN SAYS VAN HERK INVESTMENTS B.V. INCREASES STAKE IN BIOINVENT.FINANSINSPEKTIONEN SAYS VAN HERK INVESTMENTS B.V. HOLDS 127.4 MILLION SHARES IN BIOINVENT CORRESPONDING TO 14,9%.  Full Article

Bioinvent International Extends Research Collaboration And License Agreement With Pfizer Inc.
Wednesday, 1 Jul 2020 

July 1 (Reuters) - BioInvent International AB ::BIOINVENT EXTENDS RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH PFIZER INC..PURPOSE OF RESEARCH EXTENSION IS TO PERMIT COMPANIES TO FURTHER IDENTIFY AND CHARACTERIZE NEW TARGETS AND ANTIBODIES BINDING TO THESE TARGETS.  Full Article

BioInvent Successfully Completes Directed Share Issue Of About SEK 487 Mln
Tuesday, 9 Jun 2020 

June 9 (Reuters) - BioInvent International AB ::BIOINVENT SUCCESSFULLY COMPLETES A DIRECTED SHARE ISSUE OF APPROXIMATELY SEK 487 MILLION (APPROXIMATELY EUR 47 MILLION).  Full Article

Bioinvent Q1 Loss After Tax Widens To SEK 32.6 Million
Tuesday, 28 Apr 2020 

April 28 (Reuters) - BioInvent International AB ::Q1 NET SALES SEK 16.7 (17.4) MILLION.Q1 LOSS AFTER TAX SEK -32.6 (-27.8) MILLION.STILL EXPECT EARLY RESULTS FROM PHASE I OPEN LABEL STUDY WITH A COMBINATION OF BI-1206 AND RITUXIMAB FOR TREATMENT OF NHL IN H2 2020.TIMELINES ARE STILL SUBJECT TO POTENTIAL CHANGES AND WE WILL PROVIDE UPDATES AS NECESSARY.  Full Article

Bioinvent: Promising Progress In Phase I/LLA Trial Of Lead Program BI-1206 In Combination With Rituximab
Tuesday, 14 Apr 2020 

April 14 (Reuters) - BioInvent International AB ::BIOINVENT REPORTS PROMISING PROGRESS IN PHASE I/LLA TRIAL OF LEAD PROGRAM BI-1206 IN COMBINATION WITH RITUXIMAB.EARLY RESULTS FROM PHASE I PART OF TRIAL ARE ON TRACK FOR H2 2020.WE ARE CLOSELY MONITORING SPREAD OF COVID-19 AND FOR NOW, OUR ONGOING CLINICAL TRIALS AND PLANNED INITIATIONS REMAIN ON TRACK.WE ARE VERY PLEASED TO OBSERVE INITIAL SIGNS OF EFFICACY.  Full Article

BioInvent And Transgene Presents Data About BT-001
Tuesday, 3 Mar 2020 

March 3 (Reuters) - BioInvent International AB ::BIOINVENT AND TRANSGENE PRESENTS DATA ABOUT BT-001.BOTH ONCOLYTIC AND ANTI-CTLA4 THERAPEUTIC STRATEGIES THAT SUPPORT BT-001 HAVE SHOWN ACTIVITY IN HUMANS BASED ON THEIR ABILITY TO INDUCE SUBSTANTIAL CHANGE IN TUMOR MICROENVIRONMENT AND ANTITUMORAL ACTIVITY.TRANSGENE AND BIOINVENT HAVE SUBMITTED FIRST APPLICATION FOR CLINICAL TRIAL OF BT-001, AND A FIRST-IN-HUMAN TRIAL IS EXPECTED TO START BEFORE END OF 2020 IN EUROPE AND THE UNITED STATES.  Full Article

BioInvent Q4 Loss After Tax Widens To SEK 40.9 Mln
Thursday, 27 Feb 2020 

Feb 27 (Reuters) - BioInvent International AB ::BIOINVENT FINANCIAL STATEMENT JANUARY 1 - DECEMBER 31, 2019.Q4 NET SALES SEK 25.4 MILLION VERSUS SEK 10.4 MILLION YEAR AGO.Q4 LOSS AFTER TAX 40.9 MILLION VERSUS LOSS SEK 32.7 MILLION YEAR AGO.  Full Article

BRIEF-Bioinvent to launch SEK 139 mln repair rights issue

* BIOINVENT'S BOARD OF DIRECTORS RESOLVE ON A REPAIR RIGHTS ISSUE OF A MAXIMUM OF APPROX. SEK 139 MILLION, FOLLOWING THE SUCCESSFULLY COMPLETED DIRECTED SHARE ISSUE OF APPROX. SEK 487 MILLION